Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Na\uefve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
- Publication date
- 5 January 2024
- Publisher
- 'American Association for Cancer Research (AACR)'